Research progress of interleukin-1 receptor accessory protein in the pathogenesis of neuropsychiatric diseases

doi:10.3969/j.issn.1674-8115.2022.01.015

Abstract

Abstract:

Interleukin-1 receptor accessory protein (IL1RAP) is one of the important components of interleukin-1 (IL-1) signaling pathway, which can participant in the formation of IL-1/ IL-1RⅠ (interleukin-1 receptor Ⅰ)/IL1RAP complex and recruit adaptor proteins and downstream signal intermediates, further activate protein kinases, and ultimately induce the synthesis of proinflammatory mediators and the occurrence of acute inflammation response. In addition, IL1RAP is also involved in regulating the formation of neural synapses, which is an important molecular link between immune system and nervous system, and may be involved in the pathological process of neuropsychiatric diseases. This paper reviews the latest research results of IL1RAP in neuropsychiatric diseases (such as glioma, Alzheimer's disease, schizophrenia, etc.) in recent years, in order to explore the role and mechanism of IL1RAP in the pathogenesis of these diseases and provide theoretical support for its diagnosis and treatment.

Key words: interleukin-1 receptor accessory protein (IL1RAP), interleukin-1 signaling pathway, neurological disease, psychiatric disease

CLC Number:

R741.02

Peipei CHENG, Yasong DU. Research progress of interleukin-1 receptor accessory protein in the pathogenesis of neuropsychiatric diseases[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 101-106.

TrendMD

References 47

1	SIMS J E, SMITH D E. The IL-1 family: regulators of immunity[J]. Nat Rev Immunol, 2010, 10(2): 89-102.
2	WANG D, ZHANG S, LI L, et al. Structural insights into the assembly and activation of IL-1β with its receptors[J]. Nat Immunol, 2010, 11(10): 905-911.
3	COHEN P. The TLR and IL-1 signalling network at a glance[J]. J Cell Sci, 2014, 127(pt 11): 2383-2390.
4	FERRIS S P, HOFMANN J W, SOLOMON D A, et al. Characterization of gliomas: from morphology to molecules[J]. Virchows Arch, 2017, 471(2): 257-269.
5	ÅGERSTAM H, KARLSSON C, HANSEN N, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia[J]. PNAS, 2015, 112(34): 10786-10791.
6	WEI W, HUANG J, MA Y, et al. IL-1 signaling pathway molecules as key markers in childhood asthma[J]. Pediatr Allergy Immunol, 2021, 32(2): 305-313.
7	KIM S S, CHEONG J Y, LEE D, et al. Interleukin-1ß and interleukin-1 receptor accessory protein gene polymorphisms are associated with persistent hepatitis B virus infection[J]. Hepatogastroenterology, 2012, 59(113): 190-197.
8	YOSHIDA T, SHIROSHIMA T, LEE S J, et al. Interleukin-1 receptor accessory protein organizes neuronal synaptogenesis as a cell adhesion molecule[J]. J Neurosci, 2012, 32(8): 2588-2600.
9	MIGLIORINI P, ITALIANI P, PRATESI F, et al. The IL-1 family cytokines and receptors in autoimmune diseases[J]. Autoimmun Rev, 2020, 19(9): 102617.
10	GREENFEDER S A, NUNES P, KWEE L, et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex[J]. J Biol Chem, 1995, 270(23): 13757-13765.
11	ROTHWELL N J, LUHESHI G N. Interleukin 1 in the brain: biology, pathology and therapeutic target[J]. Trends Neurosci, 2000, 23(12): 618-625.
12	CAREY A, EDWARDS D K, EIDE C A, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia[J]. Cell Rep, 2017, 18(13): 3204-3218.
13	HUANG Y, SMITH D E, IBÁÑEZ-SANDOVAL O, et al. Neuron-specific effects of interleukin-1β are mediated by a novel isoform of the IL-1 receptor accessory protein[J]. J Neurosci, 2011, 31(49): 18048-18059.
14	SMITH D E, LIPSKY B P, RUSSELL C, et al. A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1[J]. Immunity, 2009, 30(6): 817-831.
15	LAYÉ S, LIÈGE S, LI K S, et al. Physiological significance of the interleukin 1 receptor accessory protein[J]. Neuroimmunomodulation, 2001, 9(4): 225-230.
16	LIÈGE S, LAYÉ S, LI K S, et al. Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1β[J]. J Neuroimmunol, 2000, 110(1/2): 134-139.
17	LUHESHI N M, KOVACS K J, LOPEZ-CASTEJON G, et al. Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues[J]. J Neuroinflammation, 2011, 8(1): 186.
18	PRIETO G A, SNIGDHA S, BAGLIETTO-VARGAS D, et al. Synapse-specific IL-1 receptor subunit reconfiguration augments vulnerability to IL-1β in the aged hippocampus[J]. PNAS, 2015, 112(36): E5078-E5087.
19	TOUZANI O, BOUTIN H, LEFEUVRE R, et al. Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor[J]. J Neurosci, 2002, 22(1): 38-43.
20	CHEN Y Y, ZHOU C X, YU Y N, et al. Variations in target gene expression and pathway profiles in the mouse hippocampus following treatment with different effective compounds for ischemia-reperfusion injury[J]. Naunyn-Schmiedeberg's Arch Pharmacol, 2012, 385(8): 797-806.
21	LASHLEY T, SCHOTT J M, WESTON P, et al. Molecular biomarkers of Alzheimer's disease: progress and prospects[J]. Dis Model Mech, 2018, 11(5): dmm031781.
22	RAMANAN V K, RISACHER S L, NHO K, et al. GWAS of longitudinal amyloid accumulation on ¹⁸F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP[J]. Brain, 2015, 138(pt 10): 3076-3088.
23	ZETTERGREN A, HÖGLUND K, KERN S, et al. Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated Tau protein[J]. Sci Rep, 2019, 9(1): 2460.
24	MACEDO A, GÓMEZ C, REBELO M Â, et al. Risk variants in three Alzheimer's disease genes show association with EEG endophenotypes[J]. J Alzheimer's Dis, 2021, 80(1): 209-223.
25	POZA J, GÓMEZ C, GARCÍA M, et al. Spatio-temporal fluctuations of neural dynamics in mild cognitive impairment and Alzheimer's disease[J]. Curr Alzheimer Res, 2017, 14(9): 924-936.
26	OSTROM Q T, GITTLEMAN H, FULOP J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012[J]. Neuro Oncol, 2015, 17Suppl 4(Suppl 4): iv1-iv62.
27	TELLINGEN OVAN, YETKIN-ARIK B, DE GOOIJER M C, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment[J]. Drug Resist Updat, 2015, 19: 1-12.
28	LI F, ZHANG W, WANG M, et al. IL1RAP regulated by PRPRD promotes gliomas progression via inducing neuronal synapse development and neuron differentiation in vitro[J]. Pathol Res Pract, 2020, 216(11): 153141.
29	GRAMATZKI D, FREI K, CATHOMAS G, et al. Interleukin-33 in human gliomas: expression and prognostic significance[J]. Oncol Lett, 2016, 12(1): 445-452.
30	JENSEN L E, MUZIO M, MANTOVANI A, et al. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein[J]. J Immunol, 2000, 164(10): 5277-5286.
31	HE J, LI X, ZHU W, et al. Research of differential expression of sIL1RAP in low-grade gliomas between children and adults[J]. Brain Tumor Pathol, 2018, 35(1): 19-28.
32	O'SHEA T M, ALLRED E N, KUBAN K C, et al. Elevated concentrations of inflammation-related proteins in postnatal blood predict severe developmental delay at 2 years of age in extremely preterm infants[J]. J Pediatr, 2012, 160(3): 395-401.e4.
33	O'LOUGHLIN E, PAKAN J M P, YILMAZER-HANKE D, et al. Acute in utero exposure to lipopolysaccharide induces inflammation in the pre-and postnatal brain and alters the glial cytoarchitecture in the developing amygdala[J]. J Neuroinflammation, 2017, 14(1): 212.
34	ARAD M, PIONTKEWITZ Y, ALBELDA N, et al. Immune activation in lactating dams alters sucklings' brain cytokines and produces non-overlapping behavioral deficits in adult female and male offspring: a novel neurodevelopmental model of sex-specific psychopathology[J]. Brain Behav Immun, 2017, 63: 35-49.
35	MA L, LI X W, ZHANG S J, et al. Interleukin-1β guides the migration of cortical neurons[J]. J Neuroinflammation, 2014, 11: 114.
36	CARRIÉ A, JUN L, BIENVENU T, et al. A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation[J]. Nat Genet, 1999, 23(1): 25-31.
37	RAMOS-BROSSIER M, MONTANI C, LEBRUN N, et al. Novel IL1RAPL1 mutations associated with intellectual disability impair synaptogenesis[J]. Hum Mol Genet, 2015, 24(4): 1106-1118.
38	GARDONI F, BORASO M, ZIANNI E, et al. Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1β and NMDA stimulation[J]. J Neuroinflammation, 2011, 8(1): 14.
39	OWEN M J, SAWA A, MORTENSEN P B. Schizophrenia[J]. Lancet, 2016, 388(10039): 86-97.
40	Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia[J]. Nat Rev Dis Primers, 2015, 1: 15067.
41	MEYER U, FELDON J. Epidemiology-driven neurodevelopmental animal models of schizophrenia[J]. Prog Neurobiol, 2010, 90(3): 285-326.
42	NA K S, JUNG H Y, KIM Y K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 48: 277-286.
43	GILMORE J H, FREDRIK JARSKOG L, VADLAMUDI S, et al. Prenatal infection and risk for schizophrenia: IL-1β, IL-6, and TNFα inhibit cortical neuron dendrite development[J]. Neuropsychopharmacology, 2004, 29(7): 1221-1229.
44	HAIJMA S V, HAREN NVAN, CAHN W, et al. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects[J]. Schizophr Bull, 2013, 39(5): 1129-1138.
45	HOPE S, HOSETH E, DIESET I, et al. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls[J]. Schizophr Res, 2015, 165(2/3): 188-194.
46	OORD E JVAN DEN, CLARK S L, XIE L Y, et al. A whole methylome CpG-SNP association study of psychosis in blood and brain tissue[J]. Schizophr Bull, 2016, 42(4): 1018-1026.
47	HOWRIGAN D P, ROSE S A, SAMOCHA K E, et al. Exome sequencing in schizophrenia-affected parent-offspring trios reveals risk conferred by protein-coding de novo mutations[J]. Nat Neurosci, 2020, 23(2): 185-193.

[1]	MA Chen-kai, MA Jie. Advances in application of induced pluripotent stem cells in neurological diseases [J]. , 2014, 34(8): 1239-.
[2]	CHEN Si-yan. Application of curcumin in treatment of neurological diseases [J]. , 2010, 30(6): 732-.